{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T09:17:14Z","timestamp":1794215834528,"version":"4.8.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma (MM) is a plasma cell malignancy defined by complex genetics and extensive patient heterogeneity. Despite a growing arsenal of approved therapies, MM remains incurable and in need of guidelines to identify effective personalized treatments. Here, we survey the ex vivo drug and immunotherapy sensitivities across 101 bone marrow samples from 70 patients with MM using multiplexed immunofluorescence, automated microscopy and deep-learning-based single-cell phenotyping. Combined with sample-matched genetics, proteotyping and cytokine profiling, we map the molecular regulatory network of drug sensitivity, implicating the DNA repair pathway and EYA3 expression in proteasome inhibitor sensitivity and major histocompatibility complex class II expression in the response to elotuzumab. Globally, ex vivo drug sensitivity associated with bone marrow microenvironmental signatures reflecting treatment stage, clonality and inflammation. Furthermore, ex vivo drug sensitivity significantly stratified clinical treatment responses, including to immunotherapy. Taken together, our study provides molecular and actionable insights into diverse treatment strategies for patients with MM.<\/jats:p>","DOI":"10.1038\/s43018-023-00544-9","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T14:16:10Z","timestamp":1682000170000},"page":"734-753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1866-4094","authenticated-orcid":false,"given":"Klara","family":"Kropivsek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kachel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6880-8020","authenticated-orcid":false,"given":"Sandra","family":"Goetze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9616-3303","authenticated-orcid":false,"given":"Rebekka","family":"Wegmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Festl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannik","family":"Severin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"van Drogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Dietliker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Tchinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Wollscheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4676-7931","authenticated-orcid":false,"given":"Markus G.","family":"Manz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3386-6583","authenticated-orcid":false,"given":"Berend","family":"Snijder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"544_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Primers 3, 1\u201320 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"544_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk, N. W. C. J., van de, Pawlyn, C. & Yong, K. L. Multiple myeloma. Lancet 397, 410\u2013427 (2021).","journal-title":"Lancet"},{"key":"544_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nri3795","volume":"15","author":"SL Nutt","year":"2015","unstructured":"Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. & Corcoran, L. M. The generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 15, 160\u2013171 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"544_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.it.2017.08.007","volume":"39","author":"WY Lam","year":"2018","unstructured":"Lam, W. Y. & Bhattacharya, D. Metabolic links between plasma cell survival, secretion, and stress. Trends Immunol. 39, 19\u201327 (2018).","journal-title":"Trends Immunol."},{"key":"544_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier, S. et al. Genomic complexity of multiple myeloma and its clinical implications. Nat. Rev. Clin. Oncol. 14, 100\u2013113 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"544_CR6","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1182\/blood-2007-02-069625","volume":"110","author":"D Gonz\u00e1lez","year":"2007","unstructured":"Gonz\u00e1lez, D. et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110, 3112\u20133121 (2007).","journal-title":"Blood"},{"key":"544_CR7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","volume":"106","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel, P. L. et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106, 296\u2013303 (2005).","journal-title":"Blood"},{"key":"544_CR8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature07064","volume":"454","author":"AL Shaffer","year":"2008","unstructured":"Shaffer, A. L. et al. IRF4 addiction in multiple myeloma. Nature 454, 226\u2013231 (2008).","journal-title":"Nature"},{"key":"544_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr, J. G. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91\u2013101 (2014).","journal-title":"Cancer Cell"},{"key":"544_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/leu.2008.259","volume":"23","author":"K Podar","year":"2009","unstructured":"Podar, K., Chauhan, D. & Anderson, K. C. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23, 10\u201324 (2009).","journal-title":"Leukemia"},{"key":"544_CR11","doi-asserted-by":"publisher","unstructured":"De Jong, M. M. E. et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat. Immunol. https:\/\/doi.org\/10.1038\/s41590-021-00931-3 (2021).","DOI":"10.1038\/s41590-021-00931-3"},{"key":"544_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22804-x","volume":"12","author":"R Liu","year":"2021","unstructured":"Liu, R. et al. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nat. Commun. 12, 2559 (2021).","journal-title":"Nat. Commun."},{"key":"544_CR13","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","volume":"20","author":"T Hideshima","year":"2001","unstructured":"Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P. & Anderson, K. C. The role of tumor necrosis factor-\u03b1 in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20, 4519\u20134527 (2001).","journal-title":"Oncogene"},{"key":"544_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.V74.1.11.11","volume":"74","author":"XG Zhang","year":"1989","unstructured":"Zhang, X. G., Klein, B. & Bataille, R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 74, 11\u201313 (1989).","journal-title":"Blood"},{"key":"544_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan, A. J. et al. Diagnosis and management of multiple myeloma: a review. JAMA 327, 464\u2013477 (2022).","journal-title":"JAMA"},{"key":"544_CR16","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","volume":"35","author":"J-J Lahuerta","year":"2017","unstructured":"Lahuerta, J.-J. et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J. Clin. Oncol. 35, 2900\u20132910 (2017).","journal-title":"J. Clin. Oncol."},{"key":"544_CR17","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal, M. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl. J. Med. 376, 1311\u20131320 (2017).","journal-title":"N. Engl. J. Med."},{"key":"544_CR18","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 1319\u20131331 (2016).","journal-title":"N. Engl. J. Med."},{"key":"544_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373, 621\u2013631 (2015).","journal-title":"N. Engl. J. Med."},{"key":"544_CR20","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo, A. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 754\u2013766 (2016).","journal-title":"N. Engl. J. Med."},{"key":"544_CR21","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst, H. M. et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373, 1207\u20131219 (2015).","journal-title":"N. Engl. J. Med."},{"key":"544_CR22","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","volume":"14","author":"ED Hsi","year":"2008","unstructured":"Hsi, E. D. et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin. Cancer Res. 14, 2775\u20132784 (2008).","journal-title":"Clin. Cancer Res."},{"key":"544_CR23","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"Y-T Tai","year":"2008","unstructured":"Tai, Y.-T. et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112, 1329\u20131337 (2008).","journal-title":"Blood"},{"key":"544_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00469-5","volume":"11","author":"PJ Teoh","year":"2021","unstructured":"Teoh, P. J. & Chng, W. J. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 11, 84 (2021).","journal-title":"Blood Cancer J."},{"key":"544_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","volume":"15","author":"SK Kumar","year":"2018","unstructured":"Kumar, S. K. & Rajkumar, S. V. The multiple myelomas \u2014 current concepts in cytogenetic classification and therapy. Nat. Rev. Clin. Oncol. 15, 409\u2013421 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"544_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/jclinpath-2015-203414","volume":"69","author":"N Nikesitch","year":"2016","unstructured":"Nikesitch, N. & Ling, S. C. W. Molecular mechanisms in multiple myeloma drug resistance. J. Clin. Pathol. 69, 97\u2013101 (2016).","journal-title":"J. Clin. Pathol."},{"key":"544_CR27","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3109\/10428194.2015.1121258","volume":"57","author":"YC Cohen","year":"2016","unstructured":"Cohen, Y. C. et al. Primary failure of bortezomib in newly diagnosed multiple myeloma\u2013understanding the magnitude, predictors, and significance. Leuk. Lymphoma 57, 1382\u20131388 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"544_CR28","doi-asserted-by":"publisher","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","volume":"118","author":"P Neri","year":"2011","unstructured":"Neri, P. et al. Bortezomib-induced \u2018BRCAness\u2019 sensitizes multiple myeloma cells to PARP inhibitors. Blood 118, 6368\u20136379 (2011).","journal-title":"Blood"},{"key":"544_CR29","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/leu.2009.8","volume":"23","author":"T R\u00fcckrich","year":"2009","unstructured":"R\u00fcckrich, T. et al. Characterization of the ubiquitin\u2013proteasome system in bortezomib-adapted cells. Leukemia 23, 1098\u20131105 (2009).","journal-title":"Leukemia"},{"key":"544_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.76","volume":"7","author":"M Chin","year":"2017","unstructured":"Chin, M. et al. Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival. Blood Cancer J. 7, e610 (2017).","journal-title":"Blood Cancer J."},{"key":"544_CR31","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1182\/bloodadvances.2018028530","volume":"3","author":"A Lakshman","year":"2019","unstructured":"Lakshman, A. et al. Impact of acquired del(17p) in multiple myeloma. Blood Adv 3, 1930\u20131938 (2019).","journal-title":"Blood Adv"},{"key":"544_CR32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3389\/fgene.2019.00861","volume":"10","author":"C Gourzones","year":"2019","unstructured":"Gourzones, C., Bret, C. & Moreaux, J. Treatment may be harmful: mechanisms\/prediction\/prevention of drug-induced DNA damage and repair in multiple myeloma. Front. Genet. 10, 861 (2019).","journal-title":"Front. Genet."},{"key":"544_CR33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467\u2013472 (2011).","journal-title":"Nature"},{"key":"544_CR34","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","volume":"24","author":"G Ledergor","year":"2018","unstructured":"Ledergor, G. et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat. Med. 24, 1867\u20131876 (2018).","journal-title":"Nat. Med."},{"key":"544_CR35","doi-asserted-by":"publisher","first-page":"20127","DOI":"10.1073\/pnas.0910957106","volume":"106","author":"JR St-Germain","year":"2009","unstructured":"St-Germain, J. R. et al. Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc. Natl Acad. Sci. USA 106, 20127\u201320132 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"544_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28515-1","volume":"13","author":"YLD Ng","year":"2022","unstructured":"Ng, Y. L. D. et al. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nat. Commun. 13, 1009 (2022).","journal-title":"Nat. Commun."},{"key":"544_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15521-4","volume":"11","author":"HH Huang","year":"2020","unstructured":"Huang, H. H. et al. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. Nat. Commun. 11, 1931 (2020).","journal-title":"Nat. Commun."},{"key":"544_CR38","doi-asserted-by":"publisher","first-page":"eabg9551","DOI":"10.1126\/sciadv.abg9551","volume":"7","author":"S Bhalla","year":"2021","unstructured":"Bhalla, S. et al. Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. Sci. Adv. 7, eabg9551 (2021).","journal-title":"Sci. Adv."},{"key":"544_CR39","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen, Y. C. et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat. Med. 27, 491\u2013503 (2021).","journal-title":"Nat. Med."},{"key":"544_CR40","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1016\/S2352-3026(17)30208-9","volume":"4","author":"B Snijder","year":"2017","unstructured":"Snijder, B. et al. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematol. 4, e595\u2013e606 (2017).","journal-title":"Lancet Haematol."},{"key":"544_CR41","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","volume":"12","author":"C Kornauth","year":"2022","unstructured":"Kornauth, C. et al. Functional precision medicine provides clinical benefit in advanced aggressive hematological cancers and identifies exceptional responders. Cancer Discov. 12, 372\u2013387 (2022).","journal-title":"Cancer Discov."},{"key":"544_CR42","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","volume":"12","author":"D Malani","year":"2022","unstructured":"Malani, D. et al. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 12, 388\u2013401 (2022).","journal-title":"Cancer Discov."},{"key":"544_CR43","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/ng.3362","volume":"47","author":"U Fischer","year":"2015","unstructured":"Fischer, U. et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat. Genet. 47, 1020\u20131029 (2015).","journal-title":"Nat. Genet."},{"key":"544_CR44","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","volume":"129","author":"V Frismantas","year":"2017","unstructured":"Frismantas, V. et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 129, e26\u2013e37 (2017).","journal-title":"Blood"},{"key":"544_CR45","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1172\/JCI93801","volume":"128","author":"S Dietrich","year":"2018","unstructured":"Dietrich, S. et al. Drug-perturbation-based stratification of blood cancer. J. Clin. Invest. 128, 427\u2013445 (2018).","journal-title":"J. Clin. Invest."},{"key":"544_CR46","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2015.184","volume":"30","author":"C Touzeau","year":"2016","unstructured":"Touzeau, C. et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia 30, 761\u2013764 (2016).","journal-title":"Leukemia"},{"key":"544_CR47","doi-asserted-by":"publisher","first-page":"56338","DOI":"10.18632\/oncotarget.17630","volume":"8","author":"MM Majumder","year":"2017","unstructured":"Majumder, M. M. et al. Identification of precision treatment strategies for relapsed\/refractory multiple myeloma by functional drug sensitivity testing. Oncotarget 8, 56338\u201356350 (2017).","journal-title":"Oncotarget"},{"key":"544_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90149-y","volume":"11","author":"C Tierney","year":"2021","unstructured":"Tierney, C. et al. Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients. Sci. Rep. 11, 12866 (2021).","journal-title":"Sci. Rep."},{"key":"544_CR49","doi-asserted-by":"publisher","unstructured":"Heinemann, T. et al. Deep morphology learning enhances ex vivo drug profiling-based precision medicine. Blood Cancer Discov. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0219 (2022).","DOI":"10.1158\/2643-3230.BCD-21-0219"},{"key":"544_CR50","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nchembio.2360","volume":"13","author":"GI Vladimer","year":"2017","unstructured":"Vladimer, G. I. et al. Global survey of the immunomodulatory potential of common drugs. Nat. Chem. Biol. 13, 681\u2013690 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"544_CR51","doi-asserted-by":"publisher","unstructured":"Shilts, J. et al. A physical wiring diagram for the human immune system. Nature https:\/\/doi.org\/10.1038\/s41586-022-05028-x (2022).","DOI":"10.1038\/s41586-022-05028-x"},{"key":"544_CR52","doi-asserted-by":"publisher","first-page":"eabn5631","DOI":"10.1126\/sciadv.abn5631","volume":"8","author":"Y Severin","year":"2022","unstructured":"Severin, Y. et al. Multiplexed high-throughput immune cell imaging reveals molecular health-associated phenotypes. Sci. Adv. 8, eabn5631 (2022).","journal-title":"Sci. Adv."},{"key":"544_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18904-9","volume":"11","author":"Y Xuan","year":"2020","unstructured":"Xuan, Y. et al. Standardization and harmonization of distributed multi-center proteotype analysis supporting precision medicine studies. Nat. Commun. 11, 5248 (2020).","journal-title":"Nat. Commun."},{"key":"544_CR54","doi-asserted-by":"crossref","unstructured":"He, K., Zhang, X., Ren, S. & Sun, J. Deep residual learning for image recognition. in 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR) 770\u2013778 (2016).","DOI":"10.1109\/CVPR.2016.90"},{"key":"544_CR55","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.morpho.2015.02.001","volume":"99","author":"B Ribourtout","year":"2015","unstructured":"Ribourtout, B. & Zandecki, M. Plasma cell morphology in multiple myeloma and related disorders. Morphologie 99, 38\u201362 (2015).","journal-title":"Morphologie"},{"key":"544_CR56","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/leu.2008.307","volume":"23","author":"A Dispenzieri","year":"2009","unstructured":"Dispenzieri, A. et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23, 215\u2013224 (2009).","journal-title":"Leukemia"},{"key":"544_CR57","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij, O. et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat. Cancer 1, 493\u2013506 (2020).","journal-title":"Nat. Cancer"},{"key":"544_CR58","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1182\/blood-2010-08-304022","volume":"117","author":"YX Zhu","year":"2011","unstructured":"Zhu, Y. X. et al. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood 117, 3847\u20133857 (2011).","journal-title":"Blood"},{"key":"544_CR59","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1002\/cti2.1007","volume":"7","author":"N Nikesitch","year":"2018","unstructured":"Nikesitch, N., Lee, J. M., Ling, S. & Roberts, T. L. Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance. Clin. Transl. Immunol. 7, e1007 (2018).","journal-title":"Clin. Transl. Immunol."},{"key":"544_CR60","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/bjh.16548","volume":"190","author":"P Storti","year":"2020","unstructured":"Storti, P. et al. CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy. Br. J. Haematol. 190, 430\u2013436 (2020).","journal-title":"Br. J. Haematol."},{"key":"544_CR61","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk, M. B. et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7, 311\u2013321 (2015).","journal-title":"MAbs"},{"key":"544_CR62","doi-asserted-by":"publisher","unstructured":"Szklarczyk, D., Gable, A. L., Nastou, K. C. & Lyon, D. The STRING database in 2021: customizable protein\u2013protein networks, and functional characterization of user-uploaded gene\/measurement sets. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkaa1074 (2021).","DOI":"10.1093\/nar\/gkaa1074"},{"key":"544_CR63","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2009.03.046","volume":"137","author":"TR Peterson","year":"2009","unstructured":"Peterson, T. R. et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137, 873\u2013886 (2009).","journal-title":"Cell"},{"key":"544_CR64","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nature07849","volume":"458","author":"PJ Cook","year":"2009","unstructured":"Cook, P. J. et al. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 458, 591\u2013596 (2009).","journal-title":"Nature"},{"key":"544_CR65","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0960-9822(00)00610-2","volume":"10","author":"TT Paull","year":"2000","unstructured":"Paull, T. T. et al. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr. Biol. 10, 886\u2013895 (2000).","journal-title":"Curr. Biol."},{"key":"544_CR66","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","volume":"166","author":"F Iorio","year":"2016","unstructured":"Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740\u2013754 (2016).","journal-title":"Cell"},{"key":"544_CR67","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1016\/j.molimm.2007.01.009","volume":"44","author":"M Zhao","year":"2007","unstructured":"Zhao, M. et al. MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-\u03b3. Mol. Immunol. 44, 2923\u20132932 (2007).","journal-title":"Mol. Immunol."},{"key":"544_CR68","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1158\/0008-5472.CAN-18-3744","volume":"79","author":"Y Xue","year":"2019","unstructured":"Xue, Y. et al. Bortezomib stabilizes and activates p53 in proliferative compartments of both normal and tumor tissues in vivo. Cancer Res. 79, 3595\u20133607 (2019).","journal-title":"Cancer Res."},{"key":"544_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54407-4","volume":"9","author":"U Munawar","year":"2019","unstructured":"Munawar, U. et al. Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model. Sci. Rep. 9, 18062 (2019).","journal-title":"Sci. Rep."},{"key":"544_CR70","doi-asserted-by":"publisher","unstructured":"Sklavenitis-Pistofidis, R., Haradhvala, N. J., Getz, G. & Ghobrial, I. M. Inflammatory stromal cells in the myeloma microenvironment. Nat. Immunol. https:\/\/doi.org\/10.1038\/s41590-021-00947-9 (2021).","DOI":"10.1038\/s41590-021-00947-9"},{"key":"544_CR71","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1084\/jem.180.4.1329","volume":"180","author":"P Silacci","year":"1994","unstructured":"Silacci, P., Mottet, A., Steimle, V., Reith, W. & Mach, B. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J. Exp. Med. 180, 1329\u20131336 (1994).","journal-title":"J. Exp. Med."},{"key":"544_CR72","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00277-019-03648-4","volume":"98","author":"A Mussetti","year":"2019","unstructured":"Mussetti, A. et al. PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression. Ann. Hematol. 98, 1713\u20131720 (2019).","journal-title":"Ann. Hematol."},{"key":"544_CR73","doi-asserted-by":"publisher","unstructured":"Meister, H. et al. Multifunctional mRNA-based CAR T cells display promising anti-tumor activity against glioblastoma. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-4384 (2022).","DOI":"10.1158\/1078-0432.ccr-21-4384"},{"key":"544_CR74","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1158\/0008-5472.CAN-09-4428","volume":"70","author":"S Chen","year":"2010","unstructured":"Chen, S. et al. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res. 70, 4318\u20134326 (2010).","journal-title":"Cancer Res."},{"key":"544_CR75","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","volume":"17","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov, D. D., Ali, S. M. & Sabatini, D. M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17, 596\u2013603 (2005).","journal-title":"Curr. Opin. Cell Biol."},{"key":"544_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2006-7-10-r100","volume":"7","author":"AE Carpenter","year":"2006","unstructured":"Carpenter, A. E. et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100 (2006).","journal-title":"Genome Biol."},{"key":"544_CR77","unstructured":"Krizhevsky, A., Sutskever, I. & Hinton, G. E. in Advances in Neural Information Processing Systems 25 (eds Pereira, F., Burges, C. J. C., Bottou, L. & Weinberger, K. Q.) 1097\u20131105 (Curran Associates, 2012)."},{"key":"544_CR78","unstructured":"Krizhevsky, A., Sutskever, I. & Hinton, G. E. in Advances in Neural Information Processing Systems (eds Pereira, F., Burges, C. J. C., Bottou, L. & Weinberger, K. Q.) 25 (Curran Associates, 2012)."},{"key":"544_CR79","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/1467-9868.00346","volume":"64","author":"JD Storey","year":"2002","unstructured":"Storey, J. D. A direct approach to false discovery rates. J. R. Stat. Soc. Series B Stat. Methodol. 64, 479\u2013498 (2002).","journal-title":"J. R. Stat. Soc. Series B Stat. Methodol."},{"key":"544_CR80","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12859-018-2435-4","volume":"19","author":"M Foroutan","year":"2018","unstructured":"Foroutan, M. et al. Single sample scoring of molecular phenotypes. BMC Bioinform. 19, 404 (2018).","journal-title":"BMC Bioinform."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00544-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00544-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00544-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T19:03:14Z","timestamp":1685041394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00544-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":80,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["544"],"URL":"https:\/\/doi.org\/10.1038\/s43018-023-00544-9","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"27 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.S. was a scientific co-founder of Allcyte, which has been acquired by Exscientia. B.S. is a shareholder of Exscientia and a co-inventor on US patent application 15\/514,045 relevant to the study. B.S. declares research funding from Roche and speaker fees from Novartis, GSK and AbbVie. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}